Immunomedics, Inc. (IMMU) Q4 2019 Results - Earnings Call Transcript

Immunomedics, Inc. (IMMU) Q4 2019 Earnings Conference Call February 27, 2020 5:00 PM ET

Company Participants

Chau Cheng - Senior Director of IR
Behzad Aghazadeh - Executive Chairman
Usama Malik - CFO and Chief Business Officer
Brendan Delaney - Chief Commercial Officer

Conference Call Participants

Tazeen Ahmad - Bank of America
Varun Kumar - Cantor Fitzgerald
Michael Schmidt - Guggenheim
Phil Nadeau - Cowen & Company
Chris Howerton - Jefferies
Emily Bodnar - Berenberg Capital

Operator

Good afternoon, ladies and gentlemen, thank you for standing by. As a reminder, this call is being recorded, today is Thursday, February 27, 2020.

At this time, I would like to turn the conference over to Chau Cheng, Senior Director of Investor Relations of Immunomedics.

Chau Cheng

Thank you, Serra. Before we begin, I’d like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and therefore actual results could differ materially from those expressed or implied on this call. For factors that could cause such differences please refer to our regulatory filings with the Securities and Exchange Commission.

With us on the call today with prepared remarks are Dr. Behzad Aghazadeh, Executive Chairman; and Usama Malik, Chief Financial Officer and Chief Business Officer. Also on the call for Q&A is Brendan Delaney, Chief Commercial Officer. Following the prepared remarks, we will open the call up for questions. Thank you.

Behzad?

Behzad Aghazadeh

Thank you, Chau. Good morning everyone, and thank you for joining us.

With the foundation we laid in 2019, 2020 promises to be an exciting year for Immunomedics. Our top priority for 2019 was to resubmit a high quality BLA for sacituzumab govitecan SG in late line metastatic triple negative breast